How Lipid Nanoparticle (LNP) Technology Meets The Delivery Need Of Breakthrough saRNA Vaccine

RNA vaccines are hugely versatile. They can potentially inoculate against any pathogen for which a protein target is known. Self-amplifying RNA (saRNA) maintains the advantages of mRNA vaccines but requires a lower dose of RNA due to its self-replicative properties. This reduces the burden of manufacturing, allowing facilities to make 100x more doses than with mRNA due to the reduced cost and time required. As a result, distributed/decentralized manufacturing and quick mass immunizations are possible in the event of a pandemic.

Explore challenges to the successful development of RNA-based drugs and vaccines as well as the advantages of utilizing lipid nanoparticle technology as a delivery platform for saRNA.